Site Editor
Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Posted: Tuesday, June 14, 2022
Combination therapy using the bispecific-antibody amivantamab-vmjw and the third-generation EGFR tyrosine kinase inhibitor lazertinib showed antitumor activity among a cohort of patients with non–small cell lung cancer (NSCLC) that had progressed on standard-of-care treatment. Catherine A. Shu, MD, of Columbia University Medical Center, New York, and colleagues presented results from this population of patients from the CHRYSALIS-2 study at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9006).
This group of 162 patients had EGFR-mutated NSCLC. Patients had been previously treated with osimertinib and platinum-based chemotherapy and experienced disease progression. A subgroup of this population (56 patients) was more heavily pretreated before enrollment. Patients received 1,050 mg of intravenous amivantamab plus 240 mg of oral lazertinib. Both investigators and a blinded independent central review assessed the response to treatment.
After a median follow-up of 10 months, the overall response rate by blinded review was 33%. One patient achieved a complete response, and 52 patients had a partial response. The clinical benefit rate was 57%, and the median duration of response was 9.6 months. Patients had a median overall survival of 14.8 months. In the heavily pretreated population, the overall response rate was 29%, with 1 complete response and 15 partial responses. The clinical benefit rate for this subgroup was 55%, and the mean duration of response was 8.6 months. In addition, 27 patients in this group had untreated brain metastases, and 26% of these patients experienced complete clearance of their brain lesions after therapy.
The most common adverse events included infusion-related reaction (65%), paronychia (49%), rash (41%), and stomatitis (39%). The most common grade ≥ 3 adverse events were infusion-related reactions (7%), acneiform dermatitis (5%), and hypoalbuminemia (4%). A total of 12% of patients discontinued both amivantamab and lazertinib due to adverse reactions, and 7% discontinued one of the drugs.
Disclosure: For a full list of authors’ disclosures, visit coi.asco.org.
JNCCN Spotlights
